MORRISTOWN, NJ and BOSTON, MA, (BIOAEGIS THERAPEUTICS) October 18, 2017 BioAegis Therapeutics Inc., a privately held biotechnology company exploiting the role of plasma gelsolin (pGSN) in augmenting innate immunity, announced that data demonstrating that “Delayed Therapy with Plasma Gelsolin Improves Survival in Murine Pneumococcal Pneumonia” was presented during ID Week, on October 4-8, 2017 in San Diego, California.

ID Week is the annual meeting sponsored by the IDSA, PIDSA, HIVMA & SHEA, organizations which represent infectious disease physicians and health care professionals.

Read the full press release here: BioAegis Therapeutics ID Week Poster